Recommended Dosage and Safety
Adequan®i.m. (POLYSULFATED GLYCOSAMINOGLYCAN) is the only disease-modifying osteoarthritis drug on the market approved by the FDA for the treatment of non-infectious degenerative joint disease. It is the only joint therapy clinically proven to relieve symptoms and treat the underlying causes of equine degenerative joint disease.
- Studies show that administering Adequan®i.m. as recommended—500 mg intramuscularly once every four days for 28 days or seven treatments—better than results with four-injection series.*
- Adequan®i.m. reaches the joint quickly. Two hours after a single i.m. injection, scintillation studies on multiple joints demonstrated beneficial levels in the synovial fluid of all joints tested.**
The recomended dosage for Adequan®i.m. is 500 mg once every four days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan®i.m. with other drugs or solvents.
Adequan®i.m. vs. Legend®
After six weeks of comparison to intravenous Legend® (INTRAVENOUS SODIUM HYALURONATE), Adequan®i.m. demonstrated, on average, a more rapid and significantly better recovery:
- Decreased lameness score
- Increased stride length
- Lowered joint flexing pain score
Click here for a full copy of this and other clinical studies.
Adequan®i.m. is safe.
You can be confident of the safety of Adequan®i.m. (POLYSULFATED GLYCOSAMINOGLYCAN). Based on clinical studies, field testing and its long safety record, there are no known contraindications for the intramuscular use of Adequan®i.m. No adverse effects were observed in clinical trials and toxicological studies in which Adequan®i.m. was administered intramuscularly at five times the recommended dose and for three times the recommended duration.
Studies have not been conducted to establish safety in breeding horses. Do not use in horses intended for human consumption.
Click on product inserts for full prescribing information.
* Mcllwraith, CW. Intra-articular and systemic medications for the treatment of equine joint disease. 1996 AAEP Proceedings 42:101-125.
**Burba, DJ, Collier, MA, et al. In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. Jrnl. of Eq. Vet. Sci. 13(12): 696-702, 1993.